Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | CPN1 | P15169 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161422 | 1.00 | PPARG (0.46) | PPARGPPARAALDH1A1PTGS1PTGS2 | |
| SCHEMBL6162102 | 1.00 | PPARG (0.46) | PPARGPPARAALDH1A1PTGS1PTGS2 | |
| SCHEMBL10594163 | 0.85 | ALDH1A1 (0.49) | PPARGPPARAALDH1A1PTGS1PTGS2 | |
| SCHEMBL4007604 | 0.85 | ALDH1A1 (0.58) | PPARGPPARAALDH1A1PTGS1KMT2A | |
| SCHEMBL306179 | 0.84 | POLB (0.51) | PPARGPPARAALDH1A1PTGS1PTGS2 | |
| SCHEMBL20004309 | 0.84 | ALDH1A1 (0.50) | PPARGPPARAALDH1A1PTGS1MAOB | |
| SCHEMBL21539091 | 0.83 | TACR1 (0.47) | PPARGPPARAALDH1A1PSEN1PSEN2 | |
| SCHEMBL11628886 | 0.83 | CPN1 (0.49) | ALDH1A1CPN1CPB2MAOBKMT2A | |
| SCHEMBL27577500 | 0.83 | ALDH1A1 (0.41) | ALDH1A1CPN1CPB2MAOBKMT2A | |
| SCHEMBL6163227 | 0.82 | SMN1; SMN2 (0.48) | ALDH1A1PTGS1PTGS2CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1486491-B1 | CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004098609-A1 | BENZOTRIAZEPINE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| CN-1325385-A | Gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-12-05 | — | — | CN | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | UACA, CPA3, HCAR1 | PPARG 967/4885PPARA 838/4885ALDH1A1 588/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | PPARG 276/4885PPARA 602/4885ALDH1A1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.